Mayne Pharma Group shares have slipped over the past week even after closing at A$3.01, leaving short term traders unimpressed. Yet the latest full year numbers tell a tougher story than the headline share price suggests. Revenue for FY26 came in at A$383.7m with underlying earnings before interest, tax, depreciation and amortisation of A$34.2m, both weaker than last year.

The real pivot is in the outlook. Consensus points to earnings decline over the next three years, even as the stock trades on a low P/E and well below an analyst discounted cash flow value. That clash between compressed margins and apparently cheap valuation is what matters now.

Is Mayne Pharma Group trading at a genuine discount or just flashing a value trap after that large one off gain and weak outlook for earnings? See how the A$3.01 share price lines up against cash flow, earnings quality and peer multiples in the valuation analysis for Mayne Pharma Group

FY 2026 Earnings Summary

• Revenue (FY 2026 vs FY 2025): A$383.7m vs. A$408.1m (decline of 6%)
• Net Income from Continuing Operations (FY 2026 vs FY 2025): A$31.2m profit vs. A$90.1m loss (returned to profit, boosted by a large one off gain of A$125.4m)
• Basic EPS (FY 2026 vs FY 2025): A$0.40 vs. a loss of A$1.14 per share (moved back into positive territory, including the impact of the large one off gain)
• Underlying EBITDA Margin (FY 2026): Underlying EBITDA of A$34.2m on A$383.7m revenue, with a gross margin of 64.7%

Prefer clean, visual charts over long blocks of earnings commentary and raw figures? View Mayne Pharma Group's full valuation picture in an easy-to-scan format in our company report for Mayne Pharma Group.

Evaluating Mayne Pharma’s Growth Milestones Against The Bull Case

The bullish story on Mayne Pharma Group hinges on women’s health and dermatology scaling into higher quality revenue with better margins while International and DistributeRx start to carry more weight. The FY26 print shows some of those building blocks in place. Women’s Health products like NEXTSTELLIS, BIJUVA and IMVEXXY each posted positive USD revenue growth, which lines up with the claim that rising awareness and label changes are supporting prescription demand. Dermatology hit a key milestone with branded mix rising from 54% to 58% and an 11% uplift in direct contribution, which supports the idea that the disintermediated model can sustain richer margins.

The newer growth engines are earlier stage but moving. DistributeRx exceeded internal expectations with around 5,000 new prescribers and roughly 60% of women’s health and dermatology volume flowing through non traditional channels. International progress is more modest but PBS backed NEXTSTELLIS uptake and the completed Salisbury upgrade give the export story tangible assets rather than just plans.

Compare Mayne Pharma Group’s internal wins on higher quality women’s health and dermatology revenue with what the street is actually baking into its models. See the consensus price target analysis for Mayne Pharma Group

Bear Case On Mayne Pharma’s Profit Quality Still In Play

The bearish view on Mayne Pharma Group focuses on weak earnings quality and a slow path to durable profitability. FY26 gives those critics fresh material. Group revenue fell 6% while underlying EBITDA dropped 27%, so operating leverage is not yet showing through even with a 64.7% gross margin. Bears have argued that revenue recognition and returns distort the picture. The A$11m hit from ANNOVERA returns and the reassessment of its earn out support that concern, particularly when management now treats it more as a niche product.

Critics also worry that higher selling and post approval study costs, plus rising International expenses, keep margins under pressure. That is visible in the flat gross profit against lower EBITDA and in International contribution moving backwards despite the Salisbury upgrade. The A$34.5m underlying operating cash flow is helpful, but does not fully settle questions on earnings quality or cash conversion.

Expose whether Mayne Pharma Group’s one off gains and forecast earnings decline are isolated or part of deeper structural issues. Review our risk analysis for Mayne Pharma Group which shows 2 important warning signs.

Take Charge Of Your Next Move

If the mix of low P/E, one off gains and forecast earnings pressure around Mayne Pharma Group has you watching closely, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for an entry point that fits your plan. Once you own it, use the Portfolio Command Center to cut through noise and focus on the key events that could shift the risk reward balance. For a broader view, lean on the Community to see how other investors are thinking through the same trade offs. By surfacing potential catalysts and risks early, you give yourself a better shot at staying ahead of the market.

Seeking Fresh Alternatives Beyond Mayne Pharma?

Markets move fast and the next breakout list does not stay under the radar for long. Check these fresh ideas before the crowd catches on and act now.

• Scan for resilient income while prices move and shortlist companies in the 8 dividend fortresses that could help keep your cash flow from getting caught flat footed.
• Spot potential early momentum in infrastructure and grid upgrades using the curated 38 power grid technology and infrastructure stocks so you can react before interest really starts flying.
• Target future facing materials exposure with the hand picked 30 best rare earth metal stocks and position yourself before sentiment swings and prices start dropping out of reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.